Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study

AIMS/INTRODUCTION: Trelagliptin is a novel once‐weekly oral dipeptidyl peptidase‐4 inhibitor for type 2 diabetes mellitus that was first approved in Japan. We evaluated long‐term safety and efficacy of trelagliptin in Japanese patients with type 2 diabetes mellitus. MATERIALS AND METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Nobuya, Sano, Hiroki, Seki, Yoshifumi, Kuroda, Shingo, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009134/
https://www.ncbi.nlm.nih.gov/pubmed/27181699
http://dx.doi.org/10.1111/jdi.12499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009134/
https://www.ncbi.nlm.nih.gov/pubmed/27181699
http://dx.doi.org/10.1111/jdi.12499

Ejemplares similares